๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Relapsed Cancer

IMA402 T Cell-Engaging Receptor Molecule (TCERยฎ) in Recurrent and/or Refractory Solid Tumors NCT05958121Phase 1, Phase 229 sites๐Ÿ“ Heidelberg๐Ÿ“ Heidelberg๐Ÿ“ Mannheim Immatics Biotechnologies GmbH ยท Tests: IMA402, IMA402 and checkpoint inhibitor, IMA402 and chemotherapy, IMA402 and IMA401, IMA402 and monoclonal antibody A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy NCT07188558Phase 336 sites๐Ÿ“ Gilbert๐Ÿ“ Scottsdale๐Ÿ“ Scottsdale Lyell Immunopharma, Inc. ยท Tests: rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites๐Ÿ“ Anchorage๐Ÿ“ Chandler๐Ÿ“ Gilbert Pfizer ยท Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML NCT05735184Phase 144 sites๐Ÿ“ Phoenix๐Ÿ“ La Jolla๐Ÿ“ Los Angeles Kura Oncology, Inc. ยท Tests: Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma NCT07284758Phase 260 sites๐Ÿ“ Huntsville๐Ÿ“ Phoenix๐Ÿ“ Scottsdale C4 Therapeutics, Inc. ยท Tests: Cemsidomide, Dexamethasone A Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory Glioma NCT07599371Phase 1, Phase 21 site๐Ÿ“ Zhengzhou The First Affiliated Hospital of Zhengzhou University ยท Tests: Ivoximab 20 mg/kg, ivgtt, Q4W, Temozolomide (TMZ) CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma NCT05948033Phase 1, Phase 21 site๐Ÿ“ Beijing Chinese PLA General Hospital ยท Tests: CD70-targeting CAR-T cells TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies NCT06484816Phase 11 site๐Ÿ“ Hangzhou Shenzhen TargetRx Co., Ltd. ยท Tests: TGRX-1942 Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma NCT05896228Phase 21 site๐Ÿ“ Miami Benjamin T Diamond, MD ยท Tests: Iberdomide, Carfilzomib, Daratumumab, Dexamethasone, Acetaminophen Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma NCT06160843Phase 21 site๐Ÿ“ Singapore National Cancer Centre, Singapore ยท Tests: Pembrolizumab IV infusion Q3W, with daily oral Olaparib. PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas NCT06530550Phase 21 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: PI3K inhibitor Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma NCT06536049Phase 1, Phase 23 sites๐Ÿ“ Minneapolis๐Ÿ“ Columbus๐Ÿ“ Richmond Yazeed Sawalha ยท Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Epcoritamab A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse NCT06643585Phase 31 site๐Ÿ“ Ulm Prof. Wolfgang Janni ยท Tests: Trastuzumab-Deruxtecan, Physicians Choice (PhC). Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. NCT04915248Phase 218 sites๐Ÿ“ Ancona๐Ÿ“ Aviano๐Ÿ“ Florence Fondazione Italiana Linfomi - ETS ยท Tests: Daratumumab, Bortezomib, Dexamethasone Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas NCT05210374Phase 11 site๐Ÿ“ Cleveland Case Comprehensive Cancer Center ยท Tests: Disulfiram, Copper Gluconate, Liposomal Doxorubicin (Doxil) CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL NCT06559189Phase 11 site๐Ÿ“ Aurora University of Colorado, Denver ยท Tests: CD19x22 CAR T A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. NCT04275518Phase 114 sites๐Ÿ“ Beijing๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou Ascentage Pharma Group Inc. ยท Tests: APG-115, Azacitidine, Cytarabine Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors NCT02508038Phase 11 site๐Ÿ“ Madison University of Wisconsin, Madison ยท Tests: TCRฮฑฮฒ+/CD19+ depleted Haploidentical HSCT, Zoledronate DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma NCT06892678Phase 1, Phase 21 site๐Ÿ“ The Bronx Montefiore Medical Center ยท Tests: DFMO Universal CAR-T Cell Therapy for MM NCT07248176NA1 site๐Ÿ“ Shanghai Bioray Laboratories ยท Tests: Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias NCT06994676Phase 111 sites๐Ÿ“ Duarte๐Ÿ“ Palo Alto๐Ÿ“ Tampa Crossbow Therapeutics, Inc. ยท Tests: CBX-250 Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma NCT05798897Phase 17 sites๐Ÿ“ Duarte๐Ÿ“ Aurora๐Ÿ“ Denver Marker Therapeutics, Inc. ยท Tests: MT-601 A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents NCT05334823Phase 216 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Chongqing Chongqing Precision Biotech Co., Ltd ยท Tests: pCAR-19B cells A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma NCT07075328Phase 1, Phase 25 sites๐Ÿ“ Fukuoka๐Ÿ“ Sapporo๐Ÿ“ Kagoshima Otsuka Medical Devices Co., Ltd. Japan ยท Tests: Drug:5-ALA, Device:Photodynamic system Pembrolizumab, Ibrutinib and Rituximab in PCNSL NCT04421560Phase 1, Phase 24 sites๐Ÿ“ Boston๐Ÿ“ Boston๐Ÿ“ New York Dana-Farber Cancer Institute ยท Tests: Ibrutinib, Pembrolizumab, Rituximab CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia NCT07361029Phase 11 site๐Ÿ“ Riyadh King Faisal Specialist Hospital & Research Center ยท Tests: CAR T cells chimeric antigen receptor cells UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies NCT06743503Phase 12 sites๐Ÿ“ Nanjing๐Ÿ“ Tianjin Nanjing IASO Biotechnology Co., Ltd. ยท Tests: UB-VV400, Rapamycin Clinical Study of U01๏ผˆssCART-19๏ผ‰ in Patients With B-Cell Lymphoma NCT07093073Phase 11 site๐Ÿ“ Shanghai Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd ยท Tests: ssCART-19 A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments NCT05714839Phase 1, Phase 244 sites๐Ÿ“ Bullhead City๐Ÿ“ Los Angeles๐Ÿ“ Pembroke Pines GlaxoSmithKline ยท Tests: Belantamab, Belantamab mafodotin, Pomalidomide, Dexamethasone A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma NCT07760454Phase 1, Phase 22 sites๐Ÿ“ Suzhou๐Ÿ“ Shanghai UCARsgen Biotech Limited ยท Tests: CT0596
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy